High body mass index (BMI) is an established risk factor of gastroesophageal refl ux symptoms (GERS). The aim of this study was to clarify if weight loss reduces GERS.
INTRODUCTION
Gastroesophageal refl ux disease (GERD) is a highly prevalent disease in Western populations ( 1, 2 ) , associated with a decreased health-related quality of life ( 3, 4 ) and an increased risk of esophageal adenocarcinoma ( 5, 6 ) . Th e Montreal defi nition and classification of GERD states that: " GERD is a condition which develops when the refl ux of stomach contents causes troublesome symptoms and / or complications " and the defi nition recognizes that heartburn and acid regurgitation are characteristic symptoms of GERD ( 7, 8 ) . Overweight, defi ned according to the World Health Organization ' s classifi cation as body mass index (BMI) of ≥ 25 kg / m 2 ( 9 ) , increases the risk of gastroesophageal refl ux symptoms (GERS) ( 10 -12 ) and is independently associated with esophageal adenocarcinoma ( 11 ) .
Th e increasing weight seen in the general population will have unfortunate eff ects on the prevalence of GERD ( 13 -15 ) . Weight loss may be of great importance in the prevention and treatment of the many individuals with GERD. Th e aim of this study was to clarify if weight loss reduces GERS in a large population-based cohort followed prospectively over time.
METHODS

Study population and design
Th e study was performed as part of a large population-based study, the Nord-Tr ø ndelag health study (the HUNT study). Th e HUNT study is an on-going prospective cohort study based Weight Loss and Reduction in Gastroesophageal Refl ux. A Prospective Population-Based Cohort Study: The HUNT Study on repeated health surveys of the entire adult population of Nord-Tr ø ndelag County, Norway. All residents in the county from 20 years of age have been invited to participate in three surveys, entitled HUNT 1 (1984 HUNT 1 ( -1986 , HUNT 2 (1995 HUNT 2 ( -1997 , and HUNT 3 (2006 HUNT 3 ( -2008 . Th e HUNT study includes data on a wide range of health-related items gathered from written questionnaires answered by the participants, clinical examinations performed by trained personnel, and blood samples taken from the participants ( 16 ) . GERS were assessed in HUNT 2 and HUNT 3, and these two surveys constituted the base of the present study. In addition, GERS were assessed in a " non responder study " (Mini-Q) aft er HUNT 3 in 2009, where those who did not participate in HUNT 3 were invited ( 2, 16 ) . Th e individuals who participated in HUNT 2 and were followed-up in Mini-Q were also eligible for inclusion in the present study ( Figure 1 ).
Assessment of GERS
GERS were assessed by a questionnaire in HUNT 2 (1995 HUNT 2 ( -1997 and HUNT 3 / Mini-Q (2006 -2009 . Th e participants replied to the question: " To what degree have you had heartburn or acid regurgitation during the previous 12 months? " with one of three response alternatives: " no complaints, " " minor complaints, " or " severe complaints. " In a validation study aft er HUNT 2, 25 % of those reporting minor complaints and 95 % of those reporting severe complaints had at least weekly symptoms ( 10 ) . In Mini-Q, where frequency of complaints was also assessed, the corresponding proportions were 31 % and 98 % ( 2 ). We defi ned " any GERS " to include all participants reporting minor or severe complaints and " severe GERS " to include only those reporting severe complaints.
Assessment of BMI
BMI equals weight in kilograms divided by the square height in meters (kg / m 2 ). Weight and height were objectively measured under standardized conditions and by trained personnel at screening stations in both HUNT 2 and HUNT 3. In Mini-Q, weight and height measurements were self-reported.
Assessment of covariables
Covariables in the analyses were chosen using accepted criteria for a confounding factor i.e., being associated with the outcome (GERS), associated with the exposure (weight loss), and not an eff ect of the exposure or outcome under study ( 17 ) . Th e variables selected as potential confounders were sex, age, cigarette smoking, alcohol consumption, education, and physical exercise. Th ese covariables were assessed through questionnaires in HUNT 3 / Mini-Q, except for education, which was assessed in HUNT 2. Th e participants reported cigarette smoking status, frequency of alcohol drinking during the previous 12 months, length of education, and average frequency of physical exercise.
Assessment of antirefl ux medication
Data on antirefl ux medication, i.e., proton pump inhibitors (PPIs), histamine-2-receptor antagonists (H2RAs), or antacids, were gathered from HUNT 3 and from the Norwegian Prescription Database (NorPD). Until 2010, proton pump inhibitors and H2RAs (except small packages of low-dose H2RAs) have only been available in Norway through a prescription from a physician, and only small packages of low-dose H2RAs and antacids have been available over the counter. In HUNT 3, the frequency of over-the-counter antirefl ux medication use was assessed through written questionnaires. Since 2004, data on all prescribed medication in Norway have been collected in the NorPD. By linkage of the HUNT study and the NorPD, data on all prescribed antirefl ux medication among the study participants were gathered. Using number of prescriptions and number of tablets in each prescription, average frequency of antirefl ux medication was estimated during the HUNT 3 study period. Th us, all antirefl ux medication should be accounted for in HUNT 3: over-the-counter use through the HUNT 3 questionnaires and prescribed use through the NorPD. Only those who were actually prescribed an antirefl ux medication were included in the data from the NorPD, and therefore it was not possible to distinguish between never users and participants with missing information on medication use. All participants with missing data on antirefl ux medication were therefore regarded as never users. 
Statistical methods
Logistic regression was used to analyze the association between weight loss and reduction of GERS, providing odds ratios (ORs) with 95 % confi dence intervals (CIs). Th e participants who had any GERS at baseline (HUNT 2) and no GERS at follow-up (HUNT 3 / Mini-Q), defi ned as " loss of any GERS, " were compared with those who had any GERS at both time points, i.e., " stable any GERS. " Th e participants who had severe GERS at baseline and no or minor GERS at follow-up, defi ned as " reduction of severe GERS, " were compared with those who had severe GERS at both time points, i.e., " stable severe GERS. " Finally, those who had severe GERS at baseline and no GERS at followup, defi ned as " loss of severe GERS, " were compared with those who had severe GERS at both time points, i.e., " stable severe GERS. " Th e absolute change in BMI units between the two time points was calculated and fi ve categories refl ecting this change were used in the analyses: < 0.5 units change (reference category), 0.5 -1.5 units decrease, > 1.5 -3.5 units decrease, > 3.5 units decrease, and ≥0.5 units increase. In the statistical model, adjustments were made by categorization of age ( < 40, 40 -49, 50 -59, 60 -69, or ≥ 70 years), cigarette smoking status (never smoker, previous smoker, or current smoker), frequency of alcohol consumption (less than weekly or at least weekly), years of education ( ≤ 12 years or > 12 years), and frequency of physical exercise (less than weekly or at least weekly). Antirefl ux medication was not considered a confounder according to the defi nition above. Instead, the analyses were stratifi ed into two groups of antirefl ux medication use at follow-up: no or less than weekly or at least weekly. Th e analyses were performed with the statistics and data analysis soft ware Stata, version 11.2 (StataCorp LP, College Station, TX).
Study approval
Th e study was approved by the Regional Committee for Medical and Health Research Ethics, Central-Norway (ID 4.2009.328). All participants in the HUNT study signed a written consent form before participating, which stated the purpose of the study and the possibility of future research and linkage to other registries.
RESULTS
Participants
In HUNT 2 (1995 HUNT 2 ( -1997 and HUNT 3 / Mini-Q (2006 -2009), 58,869 individuals (64 % response rate) and 44,997 individuals (49 % response rate) reported their complaints with GERS, respectively. Among these, 29,610 individuals participated in both surveys and were included in the present study. Th is corresponds to a response rate of 61 % at follow-up, aft er excluding the 10,535 participants in HUNT 2 who were no longer residents in the county at the time of HUNT 3 / Mini-Q or had deceased before HUNT 3 / Mini-Q (non eligible for follow-up; Figure 1 ).
Characteristics
At baseline (HUNT 2), 9,299 individuals (31.4 % ) reported any GERS (any GERS cohort) and 1,553 individuals (5.2 % ) reported severe GERS (severe GERS cohort). Of the any GERS cohort, 2,398 individuals (25.8 % ) reported no GERS at follow-up in HUNT 3 / Mini-Q, i.e., " loss of any GERS " ( Table 1 ). Of the severe GERS cohort, 284 individuals (18.3 % ) reported no GERS at follow-up in HUNT 3 / Mini-Q, i.e., " loss of severe GERS " ( Table 1 ), 729 individuals (46.9 % ) reported minor GERS, and 1,013 (65.2 % ) reported no or minor GERS, i.e., " reduction of severe GERS " ( Table 1 ) . Th e mean BMI among all the participants increased between the two time points. Th e participants with loss or reduction of GERS had a lower increase in BMI than those with stable GERS ( Table 1 ). Th ose with loss or reduction of GERS were younger, had higher education, and used less antirefl ux medication than those with stable GERS for both cohorts ( Table 1 ). Th ere was no diff erence in the proportion of current cigarette smokers among the subgroups ( Table 1 ). In the any GERS cohort, the proportion of women was higher among those with loss of GERS compared with those with stable GERS ( Table 1 ). In the severe GERS cohort, alcohol consumption was more frequent among those with loss or reduction of GERS compared with those with stable GERS, and physical exercise was more frequent among those with loss or reduction of GERS ( Table 1 ) .
Association between weight loss and GERS
In the crude analyses, without considering antirefl ux medication or any potential confounder, weight loss was dose-dependently associated with loss or reduction of GERS ( P value for trend ≤ 0.012; Table 2 ). When stratifi ed by antirefl ux medication, weight loss was associated with an increased treatment success with antirefl ux medication when used at least weekly ( Table 2 ). Among participants with no or less than weekly antirefl ux medication, there was a twofold increase in the adjusted odds of loss of any GERS among participants with > 3.5 units decrease in BMI compared with participants with < 0.5 units change in BMI (OR 1.98, 95 % CI 1.45 -2.72; Table 2 ). Among participants with at least weekly antirefl ux medication, the corresponding odds increased fourfold (OR 3.95, 95 % CI 2.03 -7.65; Table 2 ). Th e association between weight loss and any GERS was dose dependent, regardless of antirefl ux medication ( P value for trend < 0.001; Table 2 ). In the severe GERS cohort, there was no association between weight loss and GERS among participants with no or less than weekly antirefl ux medication. Th e adjusted ORs of reduction and loss of severe GERS among those with > 3.5 units decrease in BMI compared with those with < 0.5 units change in BMI was 0.58 (95 % CI 0.16 -2.10; Table 2 ) and 0.90 (95 % CI 0.32 -2.55; Table 2 ), respectively, and there was no dose-response association ( P value for trend 0.804 and 0.189, respectively; Table 2 ). However, among those with at least weekly antirefl ux medication, the corresponding OR was 2.12 (95 % CI 0.89 -5.02; Table 2 and Figure 2 ) and 3.11 (95 % CI 1.13 -8.58; Table 2 and Figure 3 ), respectively, and there was a dose-response association ( P value for trend 0.008 and 0.047, respectively; Table 2 ). As the crude and adjusted ORs were similar when stratifi ed by antirefl ux medication, only the adjusted data are presented in Table 2 .
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DISCUSSION
In this study, weight loss was dose-dependently associated with a reduction of GERS, especially among those with the highest decrease in BMI. Weight loss was also associated with an increased treatment success with antirefl ux medication.
Th e major strengths of this study are (i) the populationbased design, reducing selection bias; (ii) the large sample size, reducing the risk of chance fi ndings and making subgroup analyses possible; (iii) the prospective design, minimizing recall bias; (iv) the large selection of variables assessed in the HUNT study, making adjustments for potential confounders possible; and (v) the linkage with the NorPD, complementing the data on antirefl ux medication. Th e limitations are (i) the loss to follow-up between the two time points, making selection bias possible; Loss of any GERS: any GERS at baseline, no GERS at follow-up; Reduction of severe GERS: severe GERS at baseline, no or minor GERS at follow-up; loss of severe GERS: severe GERS at baseline, no GERS at follow-up. The severe GERS group is a subset of the any GERS group. ) or mean alcohol consumption (2.5 times / month); the proportion of women was 52 and 54 % ; the mean age was 48.5 years and 45.8 years; the proportion of never smokers was 47 and 48 % and of daily smokers 30 and 27 % ; the proportion with > 12 years of education was 21 and 24 % ; and the proportion who did no exercise weekly was 9 and 6 % , respectively. Th e 12-month recall period used in the questionnaire is a suboptimal long period to recall GERS. However, this should not be a major threat to the validity of the study, as most people with GERS, at least of a more severe type, are likely to be able to report their symptoms. Th e passage of 11 to 12 years between the surveys does not capture the short-term fl uctuations in symptoms in the individual subject. Moreover, some people with GERS might have (ii) the 12-month recall period used in the questionnaire, making recall bias possible; (iii) the long time period between the assessments of GERS, making short-term fl uctuations in GERS impossible to evaluate; (iv) residual confounding, which cannot be excluded in observational research, although the choice of covariables was restrictive to avoid spurious eff ects; and (v) self-reported height and weight in Mini-Q, reducing the measurement accuracy of BMI.
Th e Nord-Tr ø ndelag County is representative of the Norwegian population at large, making the fi ndings generalizable ( 18 ). Selection bias due to loss of follow-up is probably small as there were only minor diff erences in the distribution of the study variables among all the HUNT 2 participants ( N = 58,869) compared with the cohort that was followed-up ( N = 29,610): there was no developed Barrett ' s esophagus between the surveys, which might reduce symptoms, although the refl ux disease remains. However, this should be limited to only a few people in the study. In Mini-Q, height and weight were self-reported, reducing measurement accuracy of BMI in this subpopulation. However, the number of individuals from Mini-Q was limited to n = 938 (10.1 % ) and n = 190 (12.2 % ) in the any GERS cohort and the severe GERS cohort, respectively. Assuming that self-reported weight is an underestimate of the actual weight, this would overestimate any weight loss from baseline in the study, and dilute the eff ect of weight loss on loss or reduction of GERS, make the presented ORs closer to the null. In English, " heartburn " and " regurgitation " are known to be words that the general public not understands adequately. However, in Norwegian language, this is much less a problem. Th e Norwegian words " brystbrann " / " halsbrann " and " sure oppst ø t " used in this study are frequently used in the common language and are understood by the general public in the same way as healthcare professionals and researchers do.
Previous research on the eff ect of weight loss on GERS is limited, confl icting, and suff ers from varying defi nitions of GERD. Two randomized, double-blind, sham-controlled trials of gastric balloon distension on 42 and 28 extremely obese patients with pHverifi ed refl ux, but without grade C or D esophagitis (Los Angeles classifi cation ( 19 ) ) or large ( > 3 cm) hiatus hernia on endoscopy, found that weight loss was followed by reduced refl ux ( 20, 21 ). An uncontrolled prospective study of 34 patients (mean BMI 23.5 kg / m 2 ) with troublesome GERS, and either normal endoscopy or grade I esophagitis (Savary -Miller classifi cation ( 22 ) ), found improvement in refl ux symptom score aft er 6 weeks with a decrease of mean BMI of 1.7 units ( 23 ) . Another uncontrolled prospective study of 18 volunteers (mean BMI 43.5 kg / m 2 ) with GERS found improvement in symptom score aft er a mean of 4 days with an average weight loss of 1.7 kg ( 24 ). In the Nurses ' Health Study from the United States, there was a 36 % reduction in the risk of at least weekly GERS among women with at least a 3.5 decrease in BMI compared with those with no change in BMI (OR 0.64, 95 % CI 0.42 -0.97) ( 25 ) . However, a randomized trial of 20 obese patients (mean BMI 31.4 kg / m 2 at inclusion) with pH-verifi ed refl ux, erosive esophagitis, and daily GERS did not fi nd any eff ect on GERS with a mean decrease in BMI of 2.6 to 4.8 units ( 26 ) . Th is study included participants with hiatus hernia, which contributes to the occurrence of GERD and is irreversible with weight loss. Th e only previous population-based study of the eff ect of weight change on GERS was from the United States and followed 637 individuals over a median of 10.5 years (mean age 62 years and 53 % females at follow-up) and found no relation between weight change and change in reported GERD symptoms ( 27 ) . However, a major limitation of that study was the use of self-reported height and weight.
Our results favor the hypothesis that weight loss improves GERS. Because of the observational design of the study, strict causality cannot be implied. However, the consistent and dose-related association between weight loss and reduction of GERS, which is preserved aft er adjustment for possible important confounders, argues for a valid conclusion. Th e data also indicate that even greater benefi ts might be seen in overweight individuals who achieve a larger weight loss. According to the Montreal defi nition and classifi cation, " GERD is a condition which develops when the refl ux of stomach contents causes troublesome symptoms and / or complications " and it further states that " In population-based studies, mild symptoms occurring 2 or more days a week, or moderate / severe symptoms occurring more than 1 day a week, are oft en considered troublesome by patients " ( 8 ) . As the validation studies of our questionnaire showed that 95 -98 % of the participants who reported severe GERS had at least weekly complaints, those reporting severe GERS in our study can be regarded as having GERD according to the Montreal defi nition. It seems that the weight loss needs to be substantial to improve severe GERS. Th is is probably because of the strong association between BMI and GERS. Even BMI in the upper normal range has been shown to be associated with GERS compared with BMI in the lower normal range ( 25 ) . In addition, weight loss without regular use of antirefl ux medication does not seem to be suffi cient. Th is probably refl ects an advanced stage of disease in these subjects, i.e., esophagitis or symptoms related to the presence of hiatal hernia, which does not resolve only with weight loss. However, weight loss was associated with an increased chance of treatment success with antirefl ux medication.
CONCLUSION
In this large prospective population-based cohort study, weight loss was dose-dependently associated with reduction of GERS and increased chance of treatment success with antirefl ux medication. Th e study also suggests that patients with GERD using regular antirefl ux medication might benefi t from weight reduction. Figure 3 . Adjusted odds ratio (OR) with 95 % confi dence interval (95 % CI) for loss of severe gastroesophageal refl ux symptoms (GERS) by change in body mass index (BMI) when using at least weekly antirefl ux medication.
